📣 VC round data is live. Check it out!
- Public Comps
- Waters
Waters Valuation Multiples
Discover Waters' revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Agilent, Alcon, IDEXX Laboratories, Siemens Healthineers and more.
Waters Overview
About Waters
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.
Founded
1991
HQ

Employees
7.9K
Website
Financials (LTM)
EV
$42B
Valuation Multiples
Start free trialWaters Financials
Waters reported last 12-month revenue of $5B and EBITDA of $2B.
In the same LTM period, Waters generated $3B in gross profit, $2B in EBITDA, and $1B in net income.
Revenue (LTM)
Waters P&L
In the most recent fiscal year, Waters reported revenue of $3B and EBITDA of $1B.
Waters is profitable as of last fiscal year, with gross margin of 59%, EBITDA margin of 36%, and net margin of 25%.
Financial data powered by Morningstar, Inc.
Waters Stock Performance
Waters has current market cap of $37B, and enterprise value of $42B.
Market Cap Evolution
Waters' stock price is $371.93.
Waters share price decreased by 3.0% in the last 30 days, and increased by 6.6% in the last year.
Waters has an EPS (earnings per share) of $7.98.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $42B | $37B | -1.6% | -3.0% | 24.9% | 6.6% | $7.98 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialWaters Valuation Multiples
Waters trades at 9.2x EV/Revenue multiple, and 27.2x EV/EBITDA.
EV / Revenue (LTM)
Waters Financial Valuation Multiples
As of June 3, 2026, Waters has market cap of $37B and EV of $42B.
Waters has a P/E ratio of 35.4x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Waters Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Waters Margins & Growth Rates
Waters grew revenue by 103% and EBITDA by 83% in the last fiscal year.
In the most recent fiscal year, Waters reported gross margin of 59%, EBITDA margin of 36%, and net margin of 25%.
Waters Margins
Waters Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Waters Operational KPIs
Waters' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Waters' Rule of 40 is 136% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Waters' Rule of X is 291% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Waters Competitors
Waters competitors include Agilent, Alcon, IDEXX Laboratories, Siemens Healthineers, DexCom, GE HealthCare, Wuxi AppTec, ResMed, Mindray and Philips.
Most Waters public comparables operate across Laboratory Services, Medical Devices, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 5.7x | 5.5x | 19.8x | 18.8x | |||
| 3.4x | 3.3x | 13.1x | 12.9x | |||
| 10.3x | 9.9x | 29.4x | 28.0x | |||
| 1.6x | 1.6x | 7.9x | 7.9x | |||
| 5.9x | 5.6x | 20.1x | 18.6x | |||
| 1.8x | 1.7x | 9.6x | 9.8x | |||
| 5.9x | 5.6x | 9.7x | 11.3x | |||
| 5.0x | 4.6x | 13.3x | 11.8x | |||
This data is available for Pro users. Sign up to see all Waters competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Waters
Waters has acquired 7 companies to date.
Last acquisition by Waters was on July 14th 2025. Waters acquired Becton, Dickinson and Company (biosciences and diagnostics solutions unit) for $18B (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Waters
| Description | - | Halo Labs is a scientific instrumentation firm offering high-throughput quality control systems for biopharmaceuticals. Its Beacon platform uses optics and microfluidics for rapid particle analysis in drug formulations, detecting aggregates in under 30 minutes. Pennsylvania-headquartered since 2011, formerly Optofluidics, it supports process development for injectables and vaccines. Halo Labs partners with biotech firms for automated imaging and data reporting. | Santa Barbara-based Wyatt Company develops light scattering instrumentation and software to characterize absolute molar mass, size, charge, and interactions of macromolecules and nanoparticles in solution. The firm supplies SEC-MALS systems for size-exclusion chromatography, FFF-MALS combining field-flow fractionation with multi-angle light scattering, CG-MALS for protein-protein interaction analysis, high-throughput DLS instruments, MP-PALS for electrophoretic mobility, differential refractometers, and viscometers. Established in 1982, Wyatt Technology equips biopharmaceutical laboratories, academic researchers, and materials scientists worldwide with tools for polymer and protein analysis. | - | |
| HQ Country | |||||
| HQ City | - | Philadelphia, PA | Santa Barbara, CA | - | |
| Deal Date | 14 Jul 2025 | 20 May 2025 | 15 Feb 2023 | 1 Feb 2022 | |
| Valuation | $18B | undisclosed | $1B | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Waters acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by Waters
Waters has invested in 6 companies to date.
Latest investment by Waters was on November 18th 2021. Waters invested in LabMinds in their $6M Series A round (EV/Revenue multiple available to Pro users).
Latest Investments by Waters
| Description | - | RedShift BioAnalytics is a biopharma analytics company providing Microfluidic Modulation Spectroscopy for protein characterization. Headquartered in Burlington, Massachusetts, and founded in 2005, its MMS platform measures structural changes in biologics from early discovery through formulation. The technology detects aggregation, stability, and conformational shifts undetectable by traditional methods, serving clients developing monoclonal antibodies and vaccines. | RedShift BioAnalytics is a biopharma analytics company providing Microfluidic Modulation Spectroscopy for protein characterization. Headquartered in Burlington, Massachusetts, and founded in 2005, its MMS platform measures structural changes in biologics from early discovery through formulation. The technology detects aggregation, stability, and conformational shifts undetectable by traditional methods, serving clients developing monoclonal antibodies and vaccines. | TetraScience is a cloud platform centralizing R&D data from lab instruments, ELNs, and LIMS for life sciences companies. Boston-headquartered, the Tetra R&D Data Cloud connects over 500 instrument types from vendors like Thermo Fisher and Waters, enabling analytics across pharma firms including Pfizer and Novartis. It supports deployment in regulated environments with data harmonization. | |
| HQ Country | |||||
| HQ City | - | - | - | Boston, MA | |
| Deal Date | 18 Nov 2021 | 18 Oct 2021 | 29 Jan 2020 | 31 Oct 2019 | |
| Round | Series A | Series E | Series D | Series A | |
| Raised | $6M | $20M | $18M | $8M | |
| Investors | Red Deer Capital; Waters | Illumina Ventures; Technology Venture Partners; Waters | Waters | First Round Capital; Floodgate; Founder Collective; Underscore VC; Waters; Y Combinator | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Waters investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Waters
| When was Waters founded? | Waters was founded in 1991. |
| Where is Waters headquartered? | Waters is headquartered in United States. |
| How many employees does Waters have? | As of today, Waters has over 7K employees. |
| Who is the CEO of Waters? | Waters' CEO is Udit Batra. |
| Is Waters publicly listed? | Yes, Waters is a public company listed on NYSE. |
| What is the stock symbol of Waters? | Waters trades under WAT ticker. |
| When did Waters go public? | Waters went public in 1995. |
| Who are competitors of Waters? | Waters main competitors include Agilent, Alcon, IDEXX Laboratories, Siemens Healthineers, DexCom, GE HealthCare, Wuxi AppTec, ResMed, Mindray, Philips. |
| What is the current market cap of Waters? | Waters' current market cap is $37B. |
| What is the current revenue of Waters? | Waters' last 12 months revenue is $5B. |
| What is the current revenue growth of Waters? | Waters revenue growth (NTM/LTM) is 48%. |
| What is the current EV/Revenue multiple of Waters? | Current revenue multiple of Waters is 9.2x. |
| What is the current EBITDA of Waters? | Waters' last 12 months EBITDA is $2B. |
| What is Waters' EBITDA margin? | Waters' last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of Waters? | Current EBITDA multiple of Waters is 27.2x. |
| What is the current FCF of Waters? | Waters' last 12 months FCF is $695M. |
| What is Waters' FCF margin? | Waters' last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of Waters? | Current FCF multiple of Waters is 59.9x. |
| How many companies Waters has acquired to date? | As of June 2026, Waters has acquired 7 companies. |
| What was the largest acquisition by Waters? | $18B acquisition of Becton, Dickinson and Company (biosciences and diagnostics solutions unit) on 14th July 2025 was the largest M&A Waters has done to date. |
| What companies Waters acquired? | Waters acquired Becton, Dickinson and Company (biosciences and diagnostics solutions unit), Wyatt Company, Andrew Alliance, Expert System Solutions, MediMass, Halo Labs, and Megadalton Solutions. |
| In how many companies Waters has invested to date? | As of June 2026, Waters has invested in 6 companies. |
| What was the last Waters investment? | On 18th November 2021 Waters invested in LabMinds, participating in a $6M Series A round, alongside Red Deer Capital. |
| In what companies Waters invested in? | Waters invested in RedShift BioAnalytics, Riffyn, Andrew Alliance, Creoptix, TetraScience, and LabMinds. |
See public comps similar to Waters
Lists including Waters
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
